We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Purpose-Oriented Robot Augments Laparoscopic Surgery

By HospiMedica International staff writers
Posted on 13 Jan 2021
An affordable surgical robot brings simplicity and versatility to a range of minimally invasive laparoscopic procedures. More...


The Distalmotion (Lausanne, Switzerland) Dexter Surgical Robot is designed to reduce the complexity of robotic surgery by integrating seamlessly with all existing laparoscopic setups and workflows. Dexter is based on two fully articulated robotic arms that use single-use instruments for suturing and dissection, including a standard line-up of 8 mm vessel sealers, staplers, and monopolar and bipolar electrosurgical instruments. The robotic arms can be individually realigned to change trocar sites, and are designed to provide working space for the assistant surgeon to hold the endoscope and retraction equipment.

The mobile, adaptable, open console supports optimal ergonomic postures, providing surgeons with the choice to operate the robot in a seated or standing position. The console is draped and placed close to the patient (within the surgical field), allowing the operating team to switch between laparoscopic and robotic surgery. The modular platform can be used with any commercial laparoscopic tower, including 4k, 3D, ICG or any other current or future imaging technology. To facilitate adoption, Dexter is built on a transparent pay-per-use model that foregoes large lump-sum investment costs.

“Dexter has already garnered tremendous interest in the surgical community and we look forward to answering the increasing demand for a medical device removing the complexity out of robotic surgery to fast track its widespread adoption in minimally invasive surgical care,” said Michael Friedrich, CEO of Distalmotion. “Following the validation of our product clinical value and benefits earlier this year, I am now looking forward to starting a broader movement allowing every patient to access the benefits of robotic surgery.”

Related Links:
Distalmotion


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Trocar
TAN RoTaLock Trocar
New
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.